# Defining Mechanisms of Transformation Driven By the Zinc Finger Transcription Factor PLAGL2 in the Intestinal Epithelium

> **NIH NIH R01** · WASHINGTON UNIVERSITY · 2021 · $360,281

## Abstract

PROJECT SUMMARY/ABSTRACT
 This project will focus on understanding mechanisms of intestinal epithelial cell (IEC) transformation. We
define early features of transformation as the augmentation of proliferation, stem cell fate, and repression of
IEC differentiation. Here, we seek to understand the role of a specific transcription factor (PLAGL2) we have
recently identified as a target repressed by Let-7 microRNAs as a part of a recently published manuscript in
Stem Cell Reports, showing that PLAGL2 drives stem cell fate. Our previous studies indicate that Let-7 is a
potent repressor of tumorigenesis and intestinal stem cell fate. Many Let-7 targets have been implicated as
oncogenes in multiple tissues, including MYC and RAS, but in our models of Let-7 manipulation in the
intestine, we do not find significant effects on these targets. We present evidence that our newly identified Let-
7 target, PLAGL2, is commonly up-regulated (>60%) in pre-cancerous and cancerous colorectal tumors in
humans, with expression inversely proportional to Let-7 miRNAs. This potentially represents a major pathway
of tumorigenesis as both Let-7 and target mRNAs are deregulated in the majority of colorectal cancers (CRC),
and is thus highly relevant. In human CRC cell lines we find that PLAGL2 is necessary for driving a malignant
phenotype, while in normal IEC organoids PLAGL2 can drive early features of transformation. First, to identify
roles for PLAGL2 in IEC transformation we will look at the potential for this factor to drive tumorigenesis
through targeted over-expression in the intestine, in the context of Let-7 depletion through LIN28B over-
expression. Using a newly generated floxed allele, we will also determine whether PLAGL2 is required for
driving early stages of IEC transformation in this model. Second, we will use our novel CRISPR somatic
mutagenesis model of intestinal tumorigenesis to examine interaction and cooperation of PLAGL2 with
canonical CRC oncogenic pathways. This model randomly mutates the tumor suppressors Apc, Pten, Smad4,
and Trp53 to generate adenomas and adenocarcinomas, which allows us to study PLAGL2 across an array of
malignant stages, tumor types, in the context of different, but defined, mutations. Third, we will explore the
roles of relevant PLAGL2 transcriptional targets, including target genes we have already identified, in driving
early processes of transformation. Through new assays and reporters in organoids, we will also characterize
Wnt signaling activity in the clonogenic cell of origin that is mobilized by aberrant PLAGL2 expression. These
investigations will likely illuminate how this newly discovered Let-7 target, PLAGL2, drives pre-malignant
changes and tumorigenesis. Considering its widespread up-regulation in pre-cancerous and cancerous
growths in the intestine, PLAGL2 may represent a keystone target for therapeutic inhibition. Additionally, given
the potent effects on stem cell fate that we see driven by PLAGL2, this fact...

## Key facts

- **NIH application ID:** 10134266
- **Project number:** 5R01CA230289-03
- **Recipient organization:** WASHINGTON UNIVERSITY
- **Principal Investigator:** DEBORAH C. RUBIN
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $360,281
- **Award type:** 5
- **Project period:** 2019-04-01 → 2024-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10134266

## Citation

> US National Institutes of Health, RePORTER application 10134266, Defining Mechanisms of Transformation Driven By the Zinc Finger Transcription Factor PLAGL2 in the Intestinal Epithelium (5R01CA230289-03). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10134266. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
